Advertisement

Journal of Genetic Counseling

, Volume 24, Issue 3, pp 409–420 | Cite as

Applying Public Health Screening Criteria: How Does Universal Newborn Screening Compare to Universal Tumor Screening for Lynch Syndrome in Adults with Colorectal Cancer?

  • Deborah CragunEmail author
  • Rita D. DeBate
  • Tuya Pal
PROFESSIONAL ISSUES

Abstract

Institutions have increasingly begun to adopt universal tumor screening (UTS) programs whereby tumors from all newly diagnosed patients with colorectal cancer (CRC) are screened to identify who should be offered germline testing for Lynch syndrome (the most common cause of hereditary CRC). Given limited information about the impact of universal screening programs to detect hereditary disease in adults, we apply criteria used to evaluate public health screening programs and compare and contrast UTS with universal newborn screening (NBS) for the purpose of examining ethical implications and anticipating potential outcomes of UTS. Both UTS and a core set of NBS conditions clearly meet most of the Wilson and Jungner screening criteria. However, many state NBS panels include additional conditions that do not meet several of these criteria, and there is currently insufficient data to confirm that UTS meets some of these criteria. Comparing UTS and NBS with regard to newer screening criteria raises additional issues that require attention for both UTS and NBS. Comparisons also highlight the importance of evaluating the implementation of genomic tests to ensure or improve their effectiveness at reducing morbidity and mortality while minimizing potential harms.

Keywords

Public health genomics Lynch syndrome Newborn screening Screening criteria Tumor screening 

Notes

Acknowledgments

Support for Deborah Cragun’s time was provided, in part, by a NCI R25T training grant awarded to Moffitt Cancer Center (5R25CA147832-04).

Conflict of Interest

Deborah Cragun, Rita DeBate, and Tuya Pal report no conflicts of interest.

Human Studies and Informed Consent

No human studies were carried out by the authors for this article.

Animal Studies

No animal studies were carried out by the authors for this article.

References

  1. Andermann, A. (2008). Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bulletin of the World Health Organization, 86, 317–319. doi: 10.2471/BLT.07.050112.PubMedPubMedCentralGoogle Scholar
  2. Barrow, E., Alduaij, W., Robinson, L., Shenton, A., Clancy, T., Lalloo, F., et al. (2008). Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations. Clinical Genetics, 74(3), 233–242. doi: 10.1111/j.1399-0004.2008.01035.x.PubMedGoogle Scholar
  3. Barrow, E., Robinson, L., Alduaij, W., Shenton, A., Clancy, T., Lalloo, F., et al. (2009). Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clinical Genetics, 75(2), 141–149. doi: 10.1111/j.1399-0004.2008.01125.x.Google Scholar
  4. Beamer, L. C., Grant, M. L., Espenschied, C. R., Blazer, K. R., Hampel, H. L., Weitzel, J. N., & MacDonald, D. J. (2012). Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 30(10), 1058–1063. doi: 10.1200/JCO.2011.38.4719.Google Scholar
  5. Bellcross, C. A., Bedrosian, S. R., Daniels, E., Duquette, D., Hampel, H., Jasperson, K., et al. (2011). Implementing screening for Lynch syndrome among patients with newly diagnosed with colorectal cancer: Summary of a public health/clinical collaborative meeting. Genetics in Medicine: Official Journal of the American College of Medical Genetics, 12(4), 152–162. doi: 10.1097/GIM.0b013e31823375ea.Google Scholar
  6. Berry, S. A., Lloyd-Puryear, M. A., & Watson, M. S. (2010). Long-term follow-up of newborn screening patients. Genetics in Medicine: Official Journal of the American College of Medical Genetics, 12(12 Suppl), S267–268. doi: 10.1097/GIM.0b013e3181fea476.Google Scholar
  7. Bonadona, V., Bonaïti, B., Olschwang, S., Grandjouan, S., Huiart, L., Longy, M., et al. (2011). Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA, the Journal of the American Medical Association, 305(22), 2304–2310. doi: 10.1001/jama.2011.743.PubMedGoogle Scholar
  8. Carmichael, M. (2011). Newborn screening: a spot of trouble. Nature News, 475(7355), 156–158. doi: 10.1038/475156a.Google Scholar
  9. Cicek, M. S., Lindor, N. M., Gallinger, S., Bapat, B., Hopper, J. L., Jenkins, M. A., et al. (2011). Quality assessment and correlation of microsatellite instability and immunohistochemical markers among population- and clinic-based colorectal tumors results from the colon cancer family registry. The Journal of Molecular Diagnostics: JMD, 13(3), 271–281. doi: 10.1016/j.jmoldx.2010.12.004.PubMedGoogle Scholar
  10. Clark, A. J., Barnetson, R., Farrington, S. M., & Dunlop, M. G. (2004). Prognosis in DNA mismatch repair deficient colorectal cancer: are all MSI tumours equivalent? Familial Cancer, 3(2), 85–91. doi: 10.1023/B:FAME.0000039915.94550.cc.PubMedGoogle Scholar
  11. Cohen, S. A. (2013). Current lynch syndrome tumor screening practices: a survey of genetic counselors. Journal of Genetic Counseling. doi: 10.1007/s10897-013-9603-5.PubMedGoogle Scholar
  12. Collins, V. R., Meiser, B., Ukoumunne, O. C., Gaff, C., St John, D. J., & Halliday, J. L. (2007). The impact of predictive genetic testing for hereditary nonpolyposis colorectal cancer: three years after testing. Genetics in Medicine: Official Journal of the American College of Medical Genetics, 9(5), 290–297. doi: 10.1097/GIM.0b013e31804b45db.Google Scholar
  13. Cragun, D., Debate, R. D., Vadaparampil, S. T., Baldwin, J., Hampel, H., & Pal, T. (2014). Comparing universal Lynch syndrome tumor-screening programs to evaluate associations between implementation strategies and patient follow-through. Genetics in Medicine. doi: 10.1038/gim.2014.31.PubMedPubMedCentralGoogle Scholar
  14. De la Chapelle, A., & Hampel, H. (2010). Clinical relevance of microsatellite instability in colorectal cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 28(20), 3380–3387. doi: 10.1200/JCO.2009.27.0652.Google Scholar
  15. Dhondt, J. L. (2010). Expanded newborn screening: social and ethical issues. Journal of Inherited Metabolic Disease, 33(Suppl 2), S211–217. doi: 10.1007/s10545-010-9138-y.PubMedGoogle Scholar
  16. Faden, R. R., Holtzman, N. A., & Chwalow, A. J. (1982). Parental rights, child welfare, and public health: the case of PKU screening. American Journal of Public Health, 72(12), 1396–1400.PubMedPubMedCentralGoogle Scholar
  17. Feuchtbaum, L., Dowray, S., & Lorey, F. (2010). The context and approach for the California newborn screening short- and long-term follow-up data system: preliminary findings. Genetics in Medicine: Official Journal of the American College of Medical Genetics, 12(12 Suppl), S242–250. doi: 10.1097/GIM.0b013e3181fe5d66.Google Scholar
  18. Frazier, D. M., Millington, D. S., McCandless, S. E., Koeberl, D. D., Weavil, S. D., Chaing, S. H., & Muenzer, J. (2006). The tandem mass spectrometry newborn screening experience in North Carolina: 1997–2005. Journal of Inherited Metabolic Disease, 29(1), 76–85. doi: 10.1007/s10545-006-0228-9.PubMedGoogle Scholar
  19. Gologan, A., & Sepulveda, A. R. (2005). Microsatellite instability and DNA mismatch repair deficiency testing in hereditary and sporadic gastrointestinal cancers. Clinics in Laboratory Medicine, 25(1), 179–196. doi: 10.1016/j.cll.2004.12.001.PubMedGoogle Scholar
  20. Gudgeon, J. M., Williams, J. L., Burt, R. W., Samowitz, W. S., Snow, G. L., & Williams, M. S. (2011). Lynch syndrome screening implementation: business analysis by a healthcare system. The American Journal of Managed Care, 17(8), e288–300.PubMedGoogle Scholar
  21. Gudgeon, J. M., Belnap, T. W., Williams, J. L., & Williams, M. S. (2012). Impact of age cutoffs on a lynch syndrome screening program. Journal of Oncology Practice, 9(4), 175–179. doi: 10.1200/JOP.2012.000573.PubMedPubMedCentralGoogle Scholar
  22. Gurian, E. A., Kinnamon, D. D., Henry, J. J., & Waisbren, S. E. (2006). Expanded newborn screening for biochemical disorders: the effect of a false-positive result. Pediatrics, 117(6), 1915–1921. doi: 10.1542/peds.2005-2294.PubMedPubMedCentralGoogle Scholar
  23. Haddow, J. E., & Palomaki, G. E. (2003). ACCE: A model process for evaluating data on emerging genetic tests. In M. Khoury, J. Little, & W. Burke (Eds.), Human genome epidemiology: A scientific foundation for using genetic information to improve health and prevent disease (pp. 217–233). New York: Oxford University Press.Google Scholar
  24. Hall, M. J. (2010). Counterpoint: implementing population genetic screening for Lynch Syndrome among newly diagnosed colorectal cancer patients–will the ends justify the means? Journal of the National Comprehensive Cancer Network: JNCCN, 8(5), 606–611.PubMedGoogle Scholar
  25. Hampel, H. (2010). Point: justification for lynch syndrome screening among all patients with newly diagnosed colorectal cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 8(5), 597–601.PubMedGoogle Scholar
  26. Hampel, H., Stephens, J. A., Pukkala, E., Sankila, R., Aaltonen, L. A., Mecklin, J.-P., et al. (2005). Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology, 129(2), 415–421. doi: 10.1016/j.gastro.2005.05.011.PubMedGoogle Scholar
  27. Hampel, H., Frankel, W. L., Martin, E., Arnold, M., Khanduja, K., Kuebler, P., et al. (2008). Feasibility of screening for lynch syndrome among patients with colorectal cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 26(35), 5783–5788. doi: 10.1200/JCO.2008.17.5950.Google Scholar
  28. Harris, R., Sawaya, G. F., Moyer, V. A., & Calonge, N. (2011). Reconsidering the criteria for evaluating proposed screening programs: reflections from 4 current and former members of the U.S. preventive services task force. Epidemiologic Reviews, 33(1), 20–35. doi: 10.1093/epirev/mxr005.PubMedGoogle Scholar
  29. Hasegawa, L. E., Fergus, K. A., Ojeda, N., & Au, S. M. (2011). Parental attitudes toward ethical and social issues surrounding the expansion of newborn screening using new technologies. Public Health Genomics, 14(4–5), 298–306. doi: 10.1159/000314644.Google Scholar
  30. Heald, B., Plesec, T., Liu, X., Pai, R., Patil, D., Moline, J., et al. (2013). Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing lynch syndrome in a large academic medical center. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 31(10), 1336–1340. doi: 10.1200/JCO.2012.45.1674.Google Scholar
  31. Heiniger, L., Butow, P. N., Price, M. A., & Charles, M. (2013). Distress in unaffected individuals who decline, delay or remain ineligible for genetic testing for hereditary diseases: a systematic review. Psycho-Oncology, 22(9), 1930–1945. doi: 10.1002/pon.3235.PubMedGoogle Scholar
  32. Herman, J. G., Umar, A., Polyak, K., Graff, J. R., Ahuja, N., Issa, J.-P. J., et al. (1998). Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proceedings of the National Academy of Sciences, 95(12), 6870–6875.Google Scholar
  33. Heshka, J. T., Palleschi, C., Howley, H., Wilson, B., & Wells, P. S. (2008). A systematic review of perceived risks, psychological and behavioral impacts of genetic testing. Genetics in Medicine: Official Journal of the American College of Medical Genetics, 10(1), 19–32. doi: 10.1097/GIM.0b013e31815f524f.Google Scholar
  34. Hiatt, R. A. (2010). Invited commentary: the epicenter of translational science. American Journal of Epidemiology, 172(5), 525–527. doi: 10.1093/aje/kwq212. discussion 528–529.PubMedGoogle Scholar
  35. Hong, S. P., Min, B. S., Kim, T. I., Cheon, J. H., Kim, N. K., Kim, H., & Kim, W. H. (2012). The differential impact of microsatellite instability as a marker of prognosis and tumour response between colon cancer and rectal cancer. European Journal of Cancer (Oxford, England: 1990), 48(8), 1235–1243. doi: 10.1016/j.ejca.2011.10.005.Google Scholar
  36. Impact of expanded newborn screening--United States, 2006. (2008). MMWR. Morbidity and Mortality Weekly Report, 57(37), 1012–1015.Google Scholar
  37. Informed Consent. (n.d.). Retrieved December 27, 2013, from http://www.genome.gov/10002332.
  38. Insinga, R. P., Laessig, R. H., & Hoffman, G. L. (2002). Newborn screening with tandem mass spectrometry: examining its cost-effectiveness in the Wisconsin newborn screening panel. The Journal of Pediatrics, 141(4), 524–531. doi: 10.1067/mpd.2002.128116.PubMedGoogle Scholar
  39. Järvinen, H. J., Aarnio, M., Mustonen, H., Aktan-Collan, K., Aaltonen, L. A., Peltomäki, P., et al. (2000). Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology, 118(5), 829–834.Google Scholar
  40. Järvinen, H. J., Renkonen-Sinisalo, L., Aktán-Collán, K., Peltomäki, P., Aaltonen, L. A., & Mecklin, J. P. (2009). Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 27(28), 4793–4797. doi: 10.1200/JCO.2009.23.7784.Google Scholar
  41. Jin, M., Hampel, H., Zhou, X., Schunemann, L., Yearsley, M., & Frankel, W. L. (2013). BRAF V600E mutation analysis simplifies the testing algorithm for Lynch syndrome. American Journal of Clinical Pathology, 140(2), 177–183. doi: 10.1309/AJCPB9FOVH1HGKFR.PubMedGoogle Scholar
  42. Kempers, M. J. E., Kuiper, R. P., Ockeloen, C. W., Chappuis, P. O., Hutter, P., Rahner, N., et al. (2011). Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. The Lancet Oncology, 12(1), 49–55. doi: 10.1016/S1470-2045(10)70265-5.PubMedGoogle Scholar
  43. Kerruish, N. J., Webster, D., & Dickson, N. (2008). Information and consent for newborn screening: practices and attitudes of service providers. Journal of Medical Ethics, 34(9), 648–652. doi: 10.1136/jme.2007.023374.PubMedGoogle Scholar
  44. Kinney, A. Y., Choi, Y. A., DeVellis, B., Millikan, R., Kobetz, E., & Sandler, R. S. (2000). Attitudes toward genetic testing in patients with colorectal cancer. Cancer Practice, 8(4), 178–186.PubMedGoogle Scholar
  45. Kinney, A. Y., DeVellis, B. M., Skrzynia, C., & Millikan, R. (2001). Genetic testing for colorectal carcinoma susceptibility: focus group responses of individuals with colorectal carcinoma and first-degree relatives. Cancer, 91(1), 57–65.PubMedGoogle Scholar
  46. Ladabaum, U., Wang, G., Terdiman, J., Blanco, A., Kuppermann, M., Boland, C. R., et al. (2011). Strategies to identify the lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Annals of Internal Medicine, 155(2), 69–79. doi: 10.1059/0003-4819-155-2-201107190-00002.PubMedPubMedCentralGoogle Scholar
  47. Landsbergen, K. M., Prins, J. B., Brunner, H. G., & Hoogerbrugge, N. (2009). Genetic testing offered directly after the diagnosis of colorectal cancer: a pilot study on the reactions of patients. Genetic Counseling (Geneva, Switzerland), 20(4), 317–325.Google Scholar
  48. Lerman, C., Marshall, J., Audrain, J., & Gomez-Caminero, A. (1996). Genetic testing for colon cancer susceptibility: Anticipated reactions of patients and challenges to providers. International Journal of Cancer. Journal International Du Cancer, 69(1), 58–61. doi: 10.1002/(SICI)1097-0215(19960220)69:1<58::AID-IJC15>3.0.CO;2-G.PubMedGoogle Scholar
  49. Levy, P. A. (2010). An overview of newborn screening. Journal of Developmental and Behavioral Pediatrics: JDBP, 31(7), 622–631. doi: 10.1097/DBP.0b013e3181eedf01.PubMedGoogle Scholar
  50. Loughrey, M. B., Waring, P. M., Tan, A., Trivett, M., Kovalenko, S., Beshay, V., et al. (2007). Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer. Familial Cancer, 6(3), 301–310. doi: 10.1007/s10689-007-9124-1.PubMedGoogle Scholar
  51. Lynch, P. M. (2011). How helpful is age at colorectal cancer onset in finding HNPCC? Diseases of the Colon & Rectum, 54(5), 515–517. doi: 10.1007/DCR.0b013e31820e2f83.Google Scholar
  52. Lynch, H. T., Lynch, J. F., Snyder, C. L., & Riegert-Johnson, D. (2011). EPCAM deletions, Lynch syndrome, and cancer risk. The Lancet Oncology, 12(1), 5–6. doi: 10.1016/S1470-2045(10)70291-6.PubMedGoogle Scholar
  53. Morrison, J., Bronner, M., Leach, B. H., Downs-Kelly, E., Goldblum, J. R., & Liu, X. (2011). Lynch syndrome screening in newly diagnosed colorectal cancer in general pathology practice: from the revised Bethesda guidelines to a universal approach. Scandinavian Journal of Gastroenterology, 46(11), 1340–1348. doi: 10.3109/00365521.2011.610003.PubMedGoogle Scholar
  54. Mvundura, M., Grosse, S. D., Hampel, H., & Palomaki, G. E. (2010). The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genetics in Medicine: Official Journal of the American College of Medical Genetics, 12(2), 93–104. doi: 10.1097/GIM.0b013e3181cd666c.Google Scholar
  55. National Comprehensive Cancer Network (NCCN) Practice Guidelines Version 1.2014 Genetic/Familial High-Risk Assessment: Colorectal (2014). Retrieved April 29, 2014, from http://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf.
  56. Newborn screening: toward a uniform screening panel and system. (2006). Genetics in Medicine: Official Journal of the American College of Medical Genetics, 8 Suppl 1, 1S-252S. doi: 10.1097/01.gim.0000223891.82390.ad. Google Scholar
  57. Overbeek, L. I. H., Ligtenberg, M. J. L., Willems, R. W., Hermens, R. P. M. G., Blokx, W. A. M., Dubois, S. V., et al. (2008). Interpretation of immunohistochemistry for mismatch repair proteins is only reliable in a specialized setting. The American Journal of Surgical Pathology, 32(8), 1246–1251.PubMedGoogle Scholar
  58. Palomaki, G. E., McClain, M. R., Melillo, S., Hampel, H. L., & Thibodeau, S. N. (2009). EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genetics in Medicine: Official Journal of the American College of Medical Genetics, 11(1), 42–65. doi: 10.1097/GIM.0b013e31818fa2db.Google Scholar
  59. Peres, J. (2010). To screen or not to screen for Lynch syndrome. Journal of the National Cancer Institute, 102(18), 1382–1384. doi: 10.1093/jnci/djq372.PubMedGoogle Scholar
  60. Ramsey, S. D., Wilson, S., Spencer, A., Geidzinska, A., & Newcomb, P. (2003). Attitudes towards genetic screening for predisposition to colon cancer among cancer patients, their relatives and members of the community. results of focus group interviews. Community Genetics, 6(1), 29–36. doi: 10.1159/000069543.PubMedPubMedCentralGoogle Scholar
  61. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. (2009). Genetics in Medicine: Official Journal of the American College of Medical Genetics, 11(1), 35–41. doi:10.1097/GIM.0b013e31818fa2ff.Google Scholar
  62. Recommended Uniform Screening Panel. (n.d.). Retrieved December 27, 2013, from http://www.hrsa.gov/advisorycommittees/mchbadvisory/heritabledisorders/recommendedpanel/.
  63. Robson, M. E., Storm, C. D., Weitzel, J., Wollins, D. S., & Offit, K. (2010). American society of clinical oncology policy statement update: genetic and genomic testing for cancer susceptibility. Journal of Clinical Oncology, 28(5), 893–901. doi: 10.1200/JCO.2009.27.0660.Google Scholar
  64. Ross, L. F. (2006). Screening for conditions that do not meet the Wilson and Jungner criteria: the case of Duchenne muscular dystrophy. American Journal of Medical Genetics. Part A, 140(8), 914–922. doi: 10.1002/ajmg.a.31165.PubMedGoogle Scholar
  65. Ross, L. F. (2010). Mandatory versus voluntary consent for newborn screening? Kennedy Institute of Ethics Journal, 20(4), 299–328.PubMedGoogle Scholar
  66. Rothwell, E., Anderson, R. A., Swoboda, K. J., Stark, L., & Botkin, J. R. (2013). Public attitudes regarding a pilot study of newborn screening for spinal muscular atrophy. American Journal of Medical Genetics. Part A, 161A(4), 679–686. doi: 10.1002/ajmg.a.35756.PubMedGoogle Scholar
  67. Shia, J. (2008). Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. The Journal of Molecular Diagnostics: JMD, 10(4), 293–300. doi: 10.2353/jmoldx.2008.080031.PubMedGoogle Scholar
  68. Singh, R. H., & Hinman, A. R. (2010). Newborn dried bloodspot screening: long-term follow-up activities and information system requirements. Genetics in Medicine: Official Journal of the American College of Medical Genetics, 12(12 Suppl), S261–266. doi: 10.1097/GIM.0b013e3181fe5f6c.Google Scholar
  69. Society of Gynecologic Oncology (SGO) Clinical Practice Statement: Screening for Lynch Syndrome in Endometrial Cancer. (2014). Retrieved April 29, 2014, from http://www.sgo.org/clinical-practice/guidelines/screening-for-lynch-syndrome-in-endometrial-cancer/.
  70. Statewide Screening Initiative Launched By Ohio State Has Life-Saving Potential. (n.d.). Retrieved January 3, 2014, from http://cancer.osu.edu/mediaroom/releases/Pages/Statewit9de-Screening-Initiative-Launched-By-Ohio-State-Has-Life-Saving-Potential.aspx.
  71. Stoffel, E., Mukherjee, B., Raymond, V. M., Tayob, N., Kastrinos, F., Sparr, J., et al. (2009). Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology, 137(5), 1621–1627. doi: 10.1053/j.gastro.2009.07.039.PubMedPubMedCentralGoogle Scholar
  72. Tejpar, S., Saridaki, Z., Delorenzi, M., Bosman, F., & Roth, A. D. (2011). Microsatellite instability, prognosis and drug sensitivity of stage II and III colorectal cancer: more complexity to the puzzle. Journal of the National Cancer Institute, 103(11), 841–844. doi: 10.1093/jnci/djr170.PubMedGoogle Scholar
  73. Thomason, M. J., Lord, J., Bain, M. D., Chalmers, R. A., Littlejohns, P., Addison, G. M., et al. (1998). A systematic review of evidence for the appropriateness of neonatal screening programmes for inborn errors of metabolism. Journal of Public Health Medicine, 20(3), 331–343.PubMedGoogle Scholar
  74. Tranø, G., Sjursen, W., Wasmuth, H. H., Hofsli, E., & Vatten, L. J. (2010). Performance of clinical guidelines compared with molecular tumour screening methods in identifying possible Lynch syndrome among colorectal cancer patients: a Norwegian population-based study. British Journal of Cancer, 102(3), 482–488. doi: 10.1038/sj.bjc.6605509.PubMedPubMedCentralGoogle Scholar
  75. Umar, A., Boland, C. R., Terdiman, J. P., Syngal, S., de la Chapelle, A., Rüschoff, J., et al. (2004). Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. Journal of the National Cancer Institute, 96(4), 261–268.PubMedPubMedCentralGoogle Scholar
  76. Van Lier, M. G., Leenen, C. H., Wagner, A., Ramsoekh, D., Dubbink, H. J., van den Ouweland, A. M., et al. (2011). Yield of routine molecular analyses in colorectal cancer patients ≤70 years to detect underlying Lynch syndrome. The Journal of Pathology, 226(5), 764–774. doi: 10.1002/path.3963.Google Scholar
  77. Vellinga, A., Cormican, M., Hanahoe, B., Bennett, K., & Murphy, A. W. (2011). Opt-out as an acceptable method of obtaining consent in medical research: a short report. BMC Medical Research Methodology, 11(1), 40. doi: 10.1186/1471-2288-11-40.PubMedPubMedCentralGoogle Scholar
  78. Watson, P., Vasen, H. F. A., Mecklin, J.-P., Bernstein, I., Aarnio, M., Järvinen, H. J., et al. (2008). The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. International Journal of Cancer. Journal International Du Cancer, 123(2), 444–449. doi: 10.1002/ijc.23508.PubMedPubMedCentralGoogle Scholar
  79. Weitzel, J. N., Blazer, K. R., MacDonald, D. J., Culver, J. O., & Offit, K. (2011). Genetics, genomics, and cancer risk assessment. CA: A Cancer Journal for Clinicians, 61(5), 327–359. doi: 10.3322/caac.20128.Google Scholar
  80. Wilcken, B. (2011). Newborn screening: how are we travelling, and where should we be going? Journal of Inherited Metabolic Disease, 34(3), 569–574. doi: 10.1007/s10545-011-9326-4.PubMedGoogle Scholar
  81. Williams, J. L., & Williams, M. S. (2011). Informed consent and immunohistochemistry screening for Lynch syndrome. Genetics in Medicine: Official Journal of the American College of Medical Genetics, 13(9), 848–849. doi: 10.1097/GIM.0b013e318228efc8.Google Scholar
  82. Wilson, J. M. G., & Jungner, G. (1968). Principles and practice of screening for disease. Public health paper number 34. Geneva: WHO.Google Scholar
  83. Win, A. K., Young, J. P., Lindor, N. M., Tucker, K. M., Ahnen, D. J., Young, G. P., et al. (2012). Colorectal and other cancer risks for carriers and noncarriers from families with a dna mismatch repair gene mutation: a prospective cohort study. Journal of Clinical Oncology, 30(9), 958–964. doi: 10.1200/JCO.2011.39.5590.PubMedPubMedCentralGoogle Scholar

Copyright information

© National Society of Genetic Counselors, Inc. 2014

Authors and Affiliations

  1. 1.Department of Cancer EpidemiologyMoffitt Cancer CenterTampaUSA
  2. 2.Department of Community and Family HealthUniversity of South FloridaTampaUSA

Personalised recommendations